GSE169571 5 V 4 DEXAMETHASONE MOUSE DN (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE169571 5 V 4 DEXAMETHASONE MOUSE DN.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE169571 5 V 4 DEXAMETHASONE MOUSE DN.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE169571 5 V 4 DEXAMETHASONE MOUSE DN.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE169571 5 V 4 DEXAMETHASONE MOUSE DN.

Results found

Linked to

 

Label

Description

 

Gene

cytokine receptor like factor 2

Gene

lymphocyte antigen 6 family member G6D

Gene

Ras association domain family member 9

Gene

zinc finger protein 32

Gene

solute carrier family 6 member 9

Gene

adaptor related protein complex 5 subunit mu 1

Gene

N-alpha-acetyltransferase 40, NatD catalytic subunit

Gene

claudin 9

Gene

retinol dehydrogenase 5

Gene

chromodomain helicase DNA binding protein 2

  • Gene

    cytokine receptor like factor 2


  • Gene

    lymphocyte antigen 6 family member G6D


  • Gene

    Ras association domain family member 9


  • Gene

    zinc finger protein 32


  • Gene

    solute carrier family 6 member 9


  • Gene

    adaptor related protein complex 5 subunit mu 1


  • Gene

    N-alpha-acetyltransferase 40, NatD catalytic subunit



  • Gene

    retinol dehydrogenase 5


  • Gene

    chromodomain helicase DNA binding protein 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.